在 2026 年 6 月 13 日，关于一项具备里程碑意义的细胞重编程临床试验细节公布，该试验借由治疗首位人类受试者实现了世界首创的里程碑。这项由位于麻萨诸塞州波士顿的 Life Biosciences 所资助的试验，于 2026 年 6 月 9 日宣布对该首位患者进行了治疗。这项备受期待的基因疗法试验旨在引导老化细胞呈现更年轻的特征，标志著在人类身上测试细胞回春的首个临床步骤。

这种新型治疗方法涉及三个特定基因的标靶激活。这些基因旨在对老旧细胞进行部分重编程，使其能够恢复到年轻状态，并恢复年轻细胞特有的功能行为。科学家希望部分重编程能够使老化器官重获新生，但这项特定试验评估了激活这三个基因作为治疗人类疾病直接干预手段的效果。

该临床试验重点在于治疗青光眼，这是一种会对连接眼睛与大脑的视神经元造成损害的流行疾病，这些神经元在成年人中通常无法再生，且可能导致失明。借由表达这三个基因编码的蛋白质，该疗法旨在刺激这些视神经元的再生。此试验的成功可能为使用细胞重编程来修复先前人类不可逆的细微神经损伤奠定先例。

On June 13, 2026, details emerged regarding a landmark clinical trial of cellular reprogramming, which achieved a world-first milestone by treating its first human participant. Sponsored by Life Biosciences based in Boston, Massachusetts, the trial announced the treatment of this first patient on June 9, 2026. This highly anticipated gene therapy trial aims to coax aged cells to take on a younger identity, marking the initial clinical step in testing cellular rejuvenation in humans.

The novel therapeutic approach involves the targeted activation of three specific genes. These genes are designed to partially reprogram old cells, enabling them to revert to a youthful state and restore functional behaviors characteristic of younger cells. Scientists hope that partial reprogramming will rejuvenate aging organs, but this specific trial evaluates the activation of the three genes as a direct intervention for treating human disease.

The clinical trial focuses on treating glaucoma, a prevalent disease causing damage to neurons in the optic nerve that connect the eye to the brain, which normally do not regenerate in adults and can lead to blindness. By expressing the proteins encoded by these three genes, the therapy aims to stimulate the regeneration of these optic nerve neurons. Success in this trial could establish a precedent for using cellular reprogramming to repair previously irreversible neural damage in humans.